Mucosal-associated invariant T (MAIT) cells can be activated by viruses through a cytokine-20 dependent mechanism, and thereby protect from lethal infection. Given this, we reasoned 21 MAIT cells may have a critical role in the immunogenicity of replication-incompetent 22 adenovirus vectors, which are novel and highly potent vaccine platforms. In vitro, ChAdOx1 23 (Chimpanzee Adenovirus Ox1) induced potent activation of MAIT cells. Activation required 24 transduction of monocytes and plasmacytoid dendritic cells to produce IL-18 and IFN-a, 25 respectively. IFN-a-induced monocyte-derived TNF-a was identified as a novel intermediate 26 in this activation pathway, and activation required combinatorial signaling of all three 27 cytokines. Furthermore, ChAdOx1-induced in vivo MAIT cell activation in both mice and 28 human volunteers. Strikingly, MAIT cell activation was necessary in vivo for development of 29
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ChAdOx1-induced HCV-specific CD8 T cell responses. These findings define a novel role for 30 MAIT cells in the immunogenicity of viral vector vaccines, with potential implications for 31 future design. 32 the maximum dose ( Fig. 1A-C ). Activation in response to Ad vectors was confirmed using the 48 MR1/5-OP-RU tetramer to identify MAIT cells ( Fig. S1E ). Vd2+ T cells share many 49 characteristics with MAIT cells (8, 9) , and showed analogous Ad vector-induced activation 50 ( Fig. S1A, S1F) . 51
We tested a wider range of Ad vectors including three species C-derived vectors (weak 52 innate inducers(10-12)): Ad5(13), Ad6(13), and ChAdN13 (unpublished), and five non-53 species C vectors (strong innate inducers(10-12)): Ad35 (B)(13), Ad24 (D)(13), ChAdOx1 54 (E)(13, 14), ChAd63 (E)(13), and ChAd68 (AdC68; E)(15). In response to stimulation with the 55 various vectors there was a gradient of IFN-g, CD69, and granzyme B production by MAIT and 56 Vd2+ T cells, which resulted in greater average activation by non-species C as compared to C 57 vectors ( Fig. 1D-F; Fig. S1G -I), consistent with the above reports of differential innate immune 58 activation by these families of vectors. 59
We next determined if MAIT and Vd2+ T cells are activated following administration 60 of Ad vectors to humans. We analyzed the activation of MAIT and Vd2+ T cells and plasma 61 cytokine levels on day -1 and day 1 following immunization of humans with 5x10 10 vp of a 62 novel ChAdOx1-MenB.1 vaccine (Fig. S2A, S2B ). We observed modest, but statistically-MAIT cells (Fig. S7A ). Depletion of monocytes from PBMCs reduced MAIT cell IFN-g production 104 following IFN-a + IL-18 stimulation (Fig. S7B ), and addition of monocytes rescued this ( Fig.  105 3B), indicating a monocyte-derived, IFN-a-dependent factor. The stimulatory factor was 106 secreted, as either conditioned supernatant from IFN-a-treated monocytes (combined with 107 IL-18), or provision of PBMCs across a transwell, significantly rescued IFN-g production by 108 isolated MAIT cells ( Fig. 3C; Fig. S7C ). IFN-a-stimulated monocytes secreted multiple 109 interferon-responsive chemokines (e.g. MCP-1/CCL2), as well as TNF-a ( Fig. 3D; Fig. S7D ). 110
Addition of recombinant TNF-a or an anti-TNFR2 agonist to IFN-a + IL-18-stimulated isolated 111 MAIT cells increased IFN-g production by >300% (from 4% to 16.5% and 17.6%, respectively; 112 Fig. S7E ). We confirmed the critical role of TNF-a as the presence of anti-TNF-a 113 antibody (adalimumab) during IFN-a + IL-18 stimulation of PBMCs inhibited IFN-g production 114 by MAIT cells (Fig. S7F ). The stimulatory capacity of supernatant from IFN-a-conditioned 115 monocytes was also inhibited by the presence of adalimumab ( Fig. S7G ). TNF-a blockade 116 using either adalimumab or recombinant TNFR2-Fc fusion protein (etanercept), but not a 117 control anti-a4b7 antibody (vedolizumab), inhibited IFN-g production by MAIT cells in 118 response to ChAdOx1 ( Fig. 3F; Fig. S7H ). Depletion of monocytes reduced ChAdOx1-induced 119 TNF-a production by 94% ( Fig. 3G ). Furthermore, Ad5 induced minimal TNF-a as compared 120 with ChAdOx1 ( Fig. S7I) , consistent with the differential capacity of these two vectors to 121 stimulate IFN-a production by pDCs ( Fig. S6A) . 122 Vd2+ T cells were activated by Ad vectors through similar mechanisms ( Fig. S8A-G) . 123
Compiling the data, the activation of innate-like T cells in response to Ad vectors requires the concerted action of IFN-a, TNF-a, and IL-18 ( Fig. S9 ). These data extend prior reports of IFNgranzyme B were also significantly upregulated on iNKT cells following ChAdOx1 135 immunization, with Ad5 inducing less activation ( Fig. S10D , S10E). These findings validate the 136 use of a mouse model, as these data recapitulate the (differential) activation of MAIT cells by 137
Ad vectors. 138
Having validated the model, we next addressed the role of MAIT cells in 139 immunogenicity of Ad vector vaccines. Wildtype (WT) C57BL/6J and MR1 KO mice ( Fig. S10F -140 H)(21) were immunized intramuscularly with 10 8 IU of ChAdOx1 expressing an optimized 141 invariant chain-linked HCV antigen(22, 23), and HCV-specific immune responses were 142 measured on day 16 post-immunization. Following vaccination, MR1 KO mice had significantly 143 reduced frequencies of CD8 T cells that produced IFN-g, TNF-a, or both IFN-g and TNF-a in 144 response to HCV peptides, as compared with WT mice ( Fig. 4C-F ). This functional defect 145 appeared specific to the CD8 T cell compartment, as there was no significant reduction in the 146 frequency of HCV-specific CD4 T cells following vaccination of MR1 KO mice ( Fig. S10I ). HCV-147 specific CD8 T cells from MR1 KO mice also showed reduced degranulation, as measured by 148 CD107a (Fig. 4G ), and these cells displayed impaired differentiation towards KLRG1+ effector 149 cells ( Fig. S10J) . 150
In summary, MAIT cells are capable of sensing the diversity of the Ad vector-induced 151 innate immune activation landscape (e.g. IFN-a, TNF-a, IL-18) and can integrate these signals Unpaired T test (B,C,G,H) , Animals were immunized intramuscularly in the hind legs with 10 8 infectious units (IU) 58 of Ad5-GFP, ChAdOx1-GFP, or ChAdOx1-HCV-GT1-6_D_TM-Ii+L, as previously described (22). 59
Spleen and lymph nodes were processed as described previously(30). Briefly, tissue was 60 dissociated through a 70 µm filter and washed with R10 media. Red blood cells were lysed, 61 as needed, with 1x ACK solution for <5 min, and cells were washed an additional time with 62 R10 media before downstream applications. Liver tissue was processed as described 63 previously(31). Briefly, liver tissue was ground through a 70 µm filter, and washed once with 64 R10 media. Liver mononuclear cells (MNCs) were isolated on a 35%-70% discontinuous Percoll 65 (GE Healthcare) gradient by centrifugation at 741 g for 20 min and deceleration was without 66 the brake. The MNC layer was collected, samples were washed once with R10 media, and 67 residual red blood cells were lysed with 1x ACK solution for <5 min. After a final wash with 68 R10 media, liver MNCs were used for downstream applications. 69
Genotyping. Genotyping of MR1 KO mice was performed by PCR and gel electrophoresis, as 70 previously described(21). DNA was extracted from splenocytes using the Qiagen DNeasy 71 chamber was loaded with either autologous PBMCs or left cell-free (N=4). IFN-g production 290 by MAIT cells was assessed at 24 h following stimulation with IFN-a + IL-18 (50 ng/ml). (D) 291 CD14-purified monocytes (N=1, in duplicate) were stimulated with IFN-a (50 ng/ml) or left 292 untreated. After 24 h, supernatants were collected and used fresh for immunoblotting. 293
Relative protein concentration was calculated by quantifying pixel density. (E) CD8-294
MicroBead enriched MAIT cells (N=10) were stimulated with single or double combinations 295 of IFN-a, IL-18, TNF-a, or anti-TNFR2 agonist antibody (cytokine at 50 ng/ml and agonist 296 antibody at 2.5 µg/ml). IFN-g production by MAIT cells was measured after 24 h. (F) PBMCs 297 (N=7) were stimulated with IFN-a + IL-18 (50 ng/ml), and adalimumab (anti-TNF-a antibody; 298 10 µg/ml) was added immediately prior cytokine addition. IFN-g production by MAIT cells was 299 measured after 24 h. (G) Purified monocytes (N=4) were stimulated with IFN-a (50 ng/ml), or 300 left untreated, and after 24 h supernatants were transferred to autologous enriched MAIT 301 cells ± IL-18 (50 ng/ml) and ± adalimumab (anti-TNF-a antibody; 10 µg/ml). IFN-g production 302 by MAIT cells was measured at 24 h. 
